Aliases & Classifications for Tic Disorder

MalaCards integrated aliases for Tic Disorder:

Name: Tic Disorder 12 15 74
Tics 30 6
Behavioral Tic 74

Classifications:



External Ids:

Disease Ontology 12 DOID:2769
ICD9CM 36 307.2 307.20
MeSH 45 D013981
SNOMED-CT 69 35042001 568005
ICD10 34 F95 F95.9

Summaries for Tic Disorder

Disease Ontology : 12 A specific developmental disorder that is characterized by the persistent presence of involuntary brief movements or sounds occuring intermittently and unpredictably out of a background of normal motor activity.

MalaCards based summary : Tic Disorder, also known as tics, is related to gilles de la tourette syndrome and tardive dyskinesia, and has symptoms including ataxia, tremor and myoclonus. An important gene associated with Tic Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Circadian entrainment and Beta-Adrenergic Signaling. The drugs Clopidogrel and Ticagrelor have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and growth/size/body region

Wikipedia : 77 Tic disorders is defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM) based on... more...

Related Diseases for Tic Disorder

Diseases in the Tic Disorder family:

Chronic Tic Disorder Transient Tic Disorder

Diseases related to Tic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 161)
# Related Disease Score Top Affiliating Genes
1 gilles de la tourette syndrome 32.2 DRD2 DRD4 DRD5 HDC IMMP2L SLC6A3
2 tardive dyskinesia 30.2 DRD2 DRD3
3 early-onset schizophrenia 30.0 DRD1 DRD2
4 choreatic disease 29.9 PNKD SLC18A2
5 migraine with or without aura 1 29.8 DRD2 DRD3 DRD5
6 obsessive-compulsive disorder 29.7 DRD1 DRD2 DRD3 DRD4 SLC6A3 SLITRK1
7 restless legs syndrome 29.6 DRD2 DRD3 SLC6A3
8 oppositional defiant disorder 29.6 DRD2 DRD4 SLC6A3 TPH2
9 conduct disorder 29.5 DRD2 DRD4 DRD5 SLC6A3
10 dystonia 29.3 DRD2 DRD5 PNKD SLC6A3
11 movement disease 29.2 DRD2 DRD3 SLC18A2 SLC6A3
12 bipolar disorder 29.0 DRD2 DRD3 SLC18A2 SLC6A3
13 disease of mental health 29.0 DRD2 DRD3 DRD4 NRXN1 SLC6A3
14 attention deficit-hyperactivity disorder 28.4 DRD1 DRD2 DRD3 DRD4 DRD5 IMMP2L
15 schizophrenia 28.1 DRD1 DRD2 DRD3 DRD4 DRD5 NRXN1
16 chronic tic disorder 12.7
17 transient tic disorder 12.7
18 trigeminal neuralgia 12.1
19 chorea, benign hereditary 11.1
20 ceroid lipofuscinosis, neuronal, 4b, autosomal dominant 11.0
21 convulsions, familial infantile, with paroxysmal choreoathetosis 11.0
22 cerebral creatine deficiency syndrome 2 11.0
23 adult neuronal ceroid lipofuscinosis 11.0
24 coasy protein-associated neurodegeneration 11.0
25 pediatric acute-onset neuropsychiatric syndrome 11.0
26 pediatric autoimmune neuropsychiatric disorders associated with streptococcus infections 11.0
27 pol iii-related leukodystrophies 10.6
28 anxiety 10.3
29 intraocular pressure quantitative trait locus 10.2
30 stuttering 10.2
31 paroxysmal hemicrania 10.2
32 nodular lymphocyte predominant hodgkin lymphoma 10.2
33 hemifacial spasm 10.2
34 polysubstance abuse 10.2 DRD2 DRD3
35 myoclonus 10.2
36 delusional disorder 10.1 DRD2 DRD3 DRD4
37 migraine without aura 10.1 DRD2 DRD3 DRD4
38 heroin dependence 10.1 DRD2 DRD4
39 bruxism 10.1 DRD2 DRD3 DRD5
40 trichotillomania 10.1
41 pervasive developmental disorder 10.0
42 dementia 10.0
43 primary orthostatic tremor 10.0
44 impulse control disorder 10.0 DRD2 DRD3 DRD4 SLITRK1
45 alcohol-induced mental disorder 10.0 DRD2 SLC6A3
46 autoimmune disease 10.0
47 autism 10.0
48 autoimmune disease 1 10.0
49 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
50 autism spectrum disorder 10.0

Graphical network of the top 20 diseases related to Tic Disorder:



Diseases related to Tic Disorder

Symptoms & Phenotypes for Tic Disorder

UMLS symptoms related to Tic Disorder:


ataxia, tremor, myoclonus, dystonia, athetosis, symptoms, synkinesis, recurrent muscle twitches (symptom), tic, motor, tic, gestural, tic, transient, tic, vocal

MGI Mouse Phenotypes related to Tic Disorder:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.25 DRD1 DRD2 DRD3 DRD4 DRD5 HDC
2 growth/size/body region MP:0005378 10.11 DRD1 DRD2 DRD3 HDC HSPD1 IMMP2L
3 homeostasis/metabolism MP:0005376 10.1 DRD1 DRD2 DRD3 DRD4 HDC NRXN1
4 mortality/aging MP:0010768 9.9 DRD1 DRD2 DRD3 DRD5 HSPD1 IMMP2L
5 integument MP:0010771 9.8 DRD1 DRD2 HDC IMMP2L SLC6A3 TDO2
6 nervous system MP:0003631 9.8 DRD1 DRD2 DRD3 DRD4 DRD5 HDC
7 taste/olfaction MP:0005394 8.92 DRD2 SLC18A2 SLC6A3 TPH2

Drugs & Therapeutics for Tic Disorder

Drugs for Tic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 377)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4,Phase 3 120202-66-6, 113665-84-2 60606
2
Ticagrelor Approved Phase 4,Phase 3 274693-27-5 9871419
3
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
4
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 2078-54-8 4943
5
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Early Phase 1,Not Applicable 113775-47-6 68602 5311068
6
Clonidine Approved Phase 4 4205-90-7 2803
7
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
8
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
9
Methylphenidate Approved, Investigational Phase 4,Phase 3,Not Applicable 113-45-1 4158
10
Naproxen Approved, Vet_approved Phase 4 22204-53-1 156391 1302
11
Clavulanate Approved, Vet_approved Phase 4,Not Applicable 58001-44-8 5280980
12
Levetiracetam Approved, Investigational Phase 4 102767-28-2 441341
13
Guanfacine Approved, Investigational Phase 4,Phase 3 29110-47-2 3519
14
Aripiprazole Approved, Investigational Phase 4,Phase 3,Not Applicable 129722-12-9 60795
15
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
16
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
17
Methyltestosterone Approved Phase 4 58-18-4 6010
18
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 6013 10204
19
Testosterone enanthate Approved Phase 4 315-37-7 9416
20
Domperidone Approved, Investigational, Vet_approved Phase 4 57808-66-9 3151
21
Lansoprazole Approved, Investigational Phase 4,Phase 3 103577-45-3 3883
22
Dexlansoprazole Approved, Investigational Phase 4,Phase 3 138530-94-6, 103577-45-3 9578005
23
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
24
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
25
Haloperidol Approved Phase 4,Phase 3 52-86-8 3559
26
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
27
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
28
Amlodipine Approved Phase 4 88150-42-9 2162
29
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
30
Budesonide Approved Phase 4 51333-22-3 63006 5281004
31
Sodium Citrate Approved, Investigational Phase 4 68-04-2
32
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
33
Codeine Approved, Illicit Phase 4 76-57-3 5284371
34
Nitrous oxide Approved, Vet_approved Phase 4,Not Applicable 10024-97-2 948
35
tannic acid Approved Phase 4,Not Applicable 1401-55-4
36
Sufentanil Approved, Investigational Phase 4,Phase 3,Not Applicable,Early Phase 1 56030-54-7 41693
37
Benzocaine Approved, Investigational Phase 4,Not Applicable 94-09-7, 1994-09-7 2337
38
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
39
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
40
Cycloserine Approved Phase 4,Not Applicable 68-41-7 401 6234
41
Morphine Approved, Investigational Phase 4,Not Applicable 57-27-2 5288826
42
Ropivacaine Approved Phase 4,Not Applicable 84057-95-4 71273 175805
43
Rocuronium Approved Phase 4,Not Applicable 119302-91-9, 143558-00-3 441290
44
Midazolam Approved, Illicit Phase 4,Phase 3,Not Applicable 59467-70-8 4192
45
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
46
Flurbiprofen Approved, Investigational Phase 4,Phase 1 5104-49-4 3394
47
Ondansetron Approved Phase 4 99614-02-5 4595
48
Cefdinir Approved Phase 4 91832-40-5 6915944
49
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
50
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635

Interventional clinical trials:

(show top 50) (show all 396)
# Name Status NCT ID Phase Drugs
1 Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM) Unknown status NCT02457130 Phase 4 Ticagrelor;Clopidogrel
2 Long Term Postoperative Cognitive Dysfunction in the Elderly Patients Unknown status NCT02301676 Phase 4 Sevoflurane;propofol
3 Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Unknown status NCT00152750 Phase 4 APO-clonidine
4 Comparison of Keppra and Clonidine in the Treatment of Tics Completed NCT00370838 Phase 4 Levetiracetam;Clonidine
5 Guanfacine in Children With Tic Disorders Completed NCT01547000 Phase 4 placebo;extended-release guanfacine (Intuniv)
6 Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT00241176 Phase 4 Aripiprazole
7 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission Completed NCT01018056 Phase 4 D-serine;Riluzole;Placebo
8 Benefit of the Treatment With Testosterone in Chronic Heart Failure Testosterone Deficiency Subjects Completed NCT01813201 Phase 4 Testosterone undecanoate;Saline isotonic solution
9 Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
10 Surface Acoustic Wave Ultrasound in Trigeminal Neuralgia Pain Completed NCT01447108 Phase 4
11 Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD Completed NCT02541006 Phase 4 Tiotropium 18 mcg
12 The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity Completed NCT02958046 Phase 4 Lansoprazole/Domperidone
13 Impact of Dexmedetomidine on the Post-Operative Cognition Dysfunction(POCD) in Geriatric Patients Completed NCT02275182 Phase 4 Dexmedetomidine;Saline
14 Controlled Hypotension During Functional Endoscopic Sinus Surgery Completed NCT01956981 Phase 4 Magnesium Sulfate;Dexmedetomidine
15 Olanzapine in the Treatment of Hair Pulling (Trichotillomania) Completed NCT00182507 Phase 4 Olanzapine
16 Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
17 Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients Completed NCT03038451 Phase 4 S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet
18 Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets Completed NCT03037606 Phase 4 Rabelis DDR 50 mg Capsules;Pariet 20 mg Enteric Coated Tablets
19 Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in COPD Completed NCT03028701 Phase 4 Formoterol/Budesonide 12/400 mcg Discair
20 Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment Completed NCT02988869 Phase 4 Tiotropium/Formoterol;Tiotropium;Formoterol;Tiotropium
21 The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy Completed NCT02939495 Phase 4 Dapoxetine/Sildenafil 30/50 mg film coated tablet
22 The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity Completed NCT02689999 Phase 4 Dexrabeprazole 10 mg Enteric-Coated Tablets
23 Efficacy and Safety of Imuneks 10 mg Capsules in the Prophylaxis of Cold Completed NCT02807220 Phase 4 Imuneks 10mg
24 Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children Completed NCT00183391 Phase 4 Atomoxetine;Methylphenidate
25 Dexmedetomidine and Delirium in Patients After Cardiac Surgery Completed NCT02267538 Phase 4 dexmedetomidine hydrochloride for injection;0.9% sodium chloride for injection
26 Evaluation of NaproxenSodium and CodeinePhosphate Combination in Osteoarthritis Completed NCT02501564 Phase 4 Naproxen Sodium Codeine;Placebo
27 Dexmedetomidine and Long-term Outcome in Elderly Patients After Surgery Completed NCT02809937 Phase 4 dexmedetomidine;placebo
28 Impact of Anesthesia Maintenance Methods on Incidence of Postoperative Delirium Completed NCT02662257 Phase 4 Sevoflurane;Propofol
29 Dexmedetomidine and Long-term Outcomes in Elderly Patients After Cardiac Surgery Completed NCT03289325 Phase 4 dexmedetomidine hydrochloride for injection;0.9% sodium chloride for injection
30 Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity Completed NCT01863459 Phase 4 Lisdexamfetamine Dimesylate;placebo
31 D-Cycloserine as an Adjunct to Internet-CBT for OCD Completed NCT01649895 Phase 4 D-Cycloserine;Placebo
32 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
33 Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects With Tourette's Disorder Recruiting NCT03661983 Phase 4 Aripiprazole (OPC-14597);Placebo
34 Comparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Adults Recruiting NCT03400735 Phase 4 Cefdinir 300Mg Capsule
35 Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment Recruiting NCT03395002 Phase 4 Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Inhalation Powder;Tiotropium 18 mcg Inhalation Powder;Salmeterol/Fluticasone 50/500 mcg Inhalation Powder
36 The Safety of Dapoxetine/Tadalafil Combination Therapy Recruiting NCT03177746 Phase 4 Dapoxetine/Tadalafil 30/20 mg film coated tablet
37 Dexmedetomidine Supplemented Analgesia and 2-Year Survival After Cancer Surgery Recruiting NCT03012971 Phase 4 Dexmedetomidine supplemented morphine analgesia;Morphine analgesia
38 Dexmedetomidine Supplemented Intravenous Analgesia in Elderly After Orthopedic Surgery Recruiting NCT03629262 Phase 4 Dexmedetomidine;Placebo
39 Dexmedetomidine Combined With Ropivacaine for Postoperative Continuous Femoral Nerve Block Recruiting NCT03629483 Phase 4 Dexmedetomidine;Placebo
40 Dexmedetomidine Supplemented Analgesia and Incidence of Postoperative Delirium Recruiting NCT03012984 Phase 4 Dexmedetomidine supplemented morphine analgesia;Morphine analgesia
41 Low-dose Dexmedetomidine in Mechanically Ventilated ICU Patients Recruiting NCT03172897 Phase 4 Dexmedetomidine;Placebo (normal saline)
42 Impacts of Low-Dose Dexmedetomidine on Sleep Quality in Mechanically Ventilated ICU Patients Recruiting NCT03335527 Phase 4 Dexmedetomidine;Placebo (normal saline)
43 A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Active, not recruiting NCT03348618 Phase 4
44 Impact of Anesthesia Maintenance Methods on Long-term Survival Rate Active, not recruiting NCT02660411 Phase 4 Sevoflurane;Propofol
45 Prophylactic Penehyclidine Hydrochloride Inhalation and 3-year Outcome After Surgery Active, not recruiting NCT03868709 Phase 4 Penehyclidine inhalation;Placebo inhalation
46 Efficacy and Safety Study of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet in the Treatment of Moderate-Severe COPD. Not yet recruiting NCT03388853 Phase 4 Acetylcysteine/Doxofylline
47 Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD Not yet recruiting NCT03363503 Phase 4 Salmeterol/Fluticasone Capsair®;Salmeterol/Fluticasone Diskus®
48 Cardiac Safety of Lansoprazole and Domperidon Combination Not yet recruiting NCT03355170 Phase 4 Lansoprazole
49 Low-dose Dexmedetomidine and Postoperative Delirium After Cardiac Surgery Not yet recruiting NCT03624595 Phase 4 Dexmedetomidine;Placebo
50 Safety Study of Galantamine in Tic Disorders Terminated NCT00226824 Phase 4 galantamine

Search NIH Clinical Center for Tic Disorder

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Tic Disorder

Genetic tests related to Tic Disorder:

# Genetic test Affiliating Genes
1 Tics 30

Anatomical Context for Tic Disorder

MalaCards organs/tissues related to Tic Disorder:

42
Brain, Testes, Cortex, Kidney, Globus Pallidus, Thalamus, Colon

Publications for Tic Disorder

Articles related to Tic Disorder:

(show top 50) (show all 684)
# Title Authors Year
1
Association of Tourette Syndrome and Chronic Tic Disorder With Metabolic and Cardiovascular Disorders. ( 30640363 )
2019
2
Provisional Tic Disorder is not so transient. ( 30850688 )
2019
3
Polygenic Risk Scores Derived From a Tourette Syndrome Genome-wide Association Study Predict Presence of Tics in the Avon Longitudinal Study of Parents and Children Cohort. ( 30424865 )
2019
4
Investigating a therapist-guided, parent-assisted remote digital behavioural intervention for tics in children and adolescents-'Online Remote Behavioural Intervention for Tics' (ORBIT) trial: protocol of an internal pilot study and single-blind randomised controlled trial. ( 30610027 )
2019
5
An Adult With Obsessive-Compulsive-Related Disorders and Tics Post-Carbon Monoxide Poisoning Who Responded Ultimately to Electroconvulsive Therapy. ( 30633069 )
2019
6
Tics and stereotypies: A comparative clinical review. ( 30773283 )
2019
7
A Randomized Controlled Trial Comparing Behavioral, Educational, and Pharmacological Treatments in Youths With Chronic Tic Disorder or Tourette Syndrome. ( 29636706 )
2018
8
Seroprevalance Anti-Toxoplasma gondii antibodies in children and adolescents with tourette syndrome/chronic motor or vocal tic disorder: A case-control study. ( 29554545 )
2018
9
Phenomenology and Clinical Correlates of Stimulus-Bound Tics in Gilles de la Tourette Syndrome. ( 29988443 )
2018
10
Distinctive tics suppression network in Gilles de la Tourette syndrome distinguished from suppression of natural urges using multimodal imaging. ( 30268027 )
2018
11
Bupropion-Related Exacerbation of Tic Disorder in an Adult: A Case Report. ( 30499776 )
2018
12
An exploratory study into an adapted use of the Alert Program for tic disorder in children. ( 30501513 )
2018
13
Tics and Tourette syndrome - surplus of actions rather than disorder? ( 29278288 )
2018
14
Tourette syndrome in a longitudinal perspective. Clinical course of tics and comorbidities, coexisting psychopathologies, phenotypes and predictors. ( 29619935 )
2018
15
Tics and Tourette syndrome. ( 30294996 )
2018
16
Subjective embodiment during the rubber hand illusion predicts severity of premonitory sensations and tics in Tourette Syndrome. ( 30337222 )
2018
17
Jian-Pi-Zhi-Dong-Decoction regulates the expression of glutamate transporters to attenuate glutamate excitotoxicity and exerts anti-tics effects in Tourette syndrome model rats. ( 30587990 )
2018
18
NFκB-Mediated Invasiveness in CD133+ Pancreatic TICs Is Regulated by Autocrine and Paracrine Activation of IL1 Signaling. ( 28970361 )
2018
19
Premonitory Urge for Tics Scale (PUTS): replication and extension of psychometric properties in youth with chronic tic disorders (CTDs). ( 29185077 )
2018
20
Botulinum toxin for motor and phonic tics in Tourette's syndrome. ( 29304272 )
2018
21
Factor structure and psychometric properties of the english version of the trier inventory for chronic stress (TICS-E). ( 29409461 )
2018
22
Aripiprazole Selectively Reduces Motor Tics in a Young Animal Model for Tourette's Syndrome and Comorbid Attention Deficit and Hyperactivity Disorder. ( 29487562 )
2018
23
Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents. ( 29498507 )
2018
24
Evaluation and Adaption of the Trier Inventory for Chronic Stress (TICS) for Assessment in Competitive Sports. ( 29593611 )
2018
25
Inhibition is impaired in children with obsessive-compulsive symptoms but not in those with tics. ( 29781133 )
2018
26
Pharmacotherapies to tics: a systematic review. ( 29963275 )
2018
27
European Multicentre Tics in Children Studies (EMTICS): protocol for two cohort studies to assess risk factors for tic onset and exacerbation in children and adolescents. ( 29982875 )
2018
28
Quick Flicks: Association of Paroxysmal Kinesigenic Dyskinesia and Tics. ( 29984260 )
2018
29
A Review on Functional Analyses of Tics. ( 30373380 )
2018
30
circCTIC1 promotes the self-renewal of colon TICs through BPTF-dependent c-Myc expression. ( 30403769 )
2018
31
LncHOXA10 drives liver TICs self-renewal and tumorigenesis via HOXA10 transcription activation. ( 30545354 )
2018
32
Rapid activation of basic hydrogen peroxide by borate and efficient destruction of toxic industrial chemicals (TICs) and chemical warfare agents (CWAs). ( 30594727 )
2018
33
Merging the Pathophysiology and Pharmacotherapy of Tics. ( 30643668 )
2018
34
Adult-onset pure tic disorder after post-traumatic hypoxic lesions of the globus pallidus. ( 27887894 )
2017
35
Parental age and the risk of obsessive compulsive disorder and Tourette syndrome / chronic tic disorder in a nationwide population-based sample. ( 28738196 )
2017
36
Revisiting the co-existence of Attention-Deficit/Hyperactivity Disorder and Chronic Tic Disorder in childhood-The case of colour discrimination, sustained attention and interference control. ( 28594866 )
2017
37
Very Early-onset Schizophrenia with Secondary Onset Tic Disorder. ( 28852253 )
2017
38
Parental Psychopathology and Tourette Syndrome/Chronic Tic Disorder in Offspring: A Nationwide Case-Control Study. ( 28335873 )
2017
39
Chronic recurrent dislocation of the temporomandibular joint secondary to a complex facial tic disorder. ( 29017736 )
2017
40
The PNKD gene is associated with Tourette Disorder or Tic disorder in a multiplex family. ( 28894297 )
2017
41
Pediatric Tourette Syndrome: A Tic Disorder with a Tricky Presentation. ( 28611559 )
2017
42
Parsing the phenotype of obsessive-compulsive tic disorder (OCTD): a multidisciplinary consensus. ( 28379724 )
2017
43
Toward a Multifactorial Conception of the Gilles de la Tourette Syndrome and Persistent Chronic Tic Disorder. ( 28574423 )
2017
44
Deep Brain Stimulation of the H Fields of Forel Alleviates Tics in Tourette Syndrome. ( 28659777 )
2017
45
Premonitory urges and tics in Tourette syndrome: computational mechanisms and neural correlates. ( 29017141 )
2017
46
A marked point process approach for identifying neural correlates of tics in Tourette Syndrome. ( 29060866 )
2017
47
Fear of fear, severe tics and deep brain stimulation in childhood Tourette Syndrome: The long and winding road. ( 28012699 )
2017
48
Moderators and predictors of response to behavior therapy for tics in Tourette syndrome. ( 28202705 )
2017
49
Persistent Tics, Tourette Syndrome, and Psychopathology: Where Are We Now, and Where Are We Going? ( 28335870 )
2017
50
Dysfunctions of the basal ganglia-cerebellar-thalamo-cortical system produce motor tics in Tourette syndrome. ( 28358814 )
2017

Variations for Tic Disorder

ClinVar genetic disease variations for Tic Disorder:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 Translocation Likely pathogenic
2 46;XY;t(3;18)(q13.31;q22.1)dn Translocation Pathogenic

Expression for Tic Disorder

Search GEO for disease gene expression data for Tic Disorder.

Pathways for Tic Disorder

Pathways related to Tic Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.67 DRD1 DRD2 DRD3 DRD4 DRD5 SLC18A2
2
Show member pathways
12.59 DRD1 DRD2 DRD3 DRD4 DRD5
3 12.08 DRD1 DRD2 DRD3 DRD4 DRD5
4
Show member pathways
11.98 DRD1 DRD2 DRD4 DRD5
6
Show member pathways
11.77 DRD1 DRD2 SLC18A2 SLC6A3
7
Show member pathways
11.68 DRD2 DRD3 DRD4 SLC18A2
8
Show member pathways
11.4 DRD1 DRD2 DRD3 DRD4 DRD5
9 11.31 DRD1 DRD2 HSPD1
10
Show member pathways
11.24 SLC6A3 TDO2 TPH2
11 11 SLC18A2 SLC6A3
12 10.96 SLC18A2 TPH2
13 10.27 DRD1 DRD2 DRD3 DRD5

GO Terms for Tic Disorder

Cellular components related to Tic Disorder according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.92 DRD1 DRD2 DRD3 DRD4 DRD5 NRXN1
2 endocytic vesicle GO:0030139 9.63 DRD2 DRD3 NRXN1
3 glutamatergic synapse GO:0098978 9.63 DRD1 DRD2 DRD3 DRD4 NRXN1 SLITRK1
4 ciliary membrane GO:0060170 9.61 DRD1 DRD2 DRD5
5 integral component of postsynaptic membrane GO:0099055 9.58 DRD1 DRD2 SLC6A3
6 integral component of presynaptic membrane GO:0099056 9.56 DRD1 DRD2 NRXN1 SLC6A3
7 non-motile cilium GO:0097730 9.54 DRD1 DRD2 DRD5
8 GABA-ergic synapse GO:0098982 9.35 DRD1 DRD2 DRD3 NRXN1 SLITRK1
9 dopaminergic synapse GO:0098691 8.92 DRD2 DRD3 SLC18A2 SLC6A3
10 membrane GO:0016020 10.29 DRD1 DRD2 DRD3 DRD4 DRD5 HSPD1
11 integral component of membrane GO:0016021 10.24 DRD1 DRD2 DRD3 DRD4 DRD5 IMMP2L

Biological processes related to Tic Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.98 DRD4 DRD5 NRXN1 SLC18A2
2 response to drug GO:0042493 9.91 DRD1 DRD2 DRD3 SLC6A3
3 response to ethanol GO:0045471 9.88 DRD2 DRD3 SLC6A3
4 locomotory behavior GO:0007626 9.88 DRD1 DRD2 DRD3 SLC18A2 SLC6A3
5 cellular calcium ion homeostasis GO:0006874 9.87 DRD3 DRD4 DRD5
6 synapse assembly GO:0007416 9.86 DRD1 DRD2 NRXN1 SLITRK1
7 learning GO:0007612 9.83 DRD1 DRD3 NRXN1
8 social behavior GO:0035176 9.82 DRD3 DRD4 NRXN1
9 visual learning GO:0008542 9.81 DRD1 DRD2 DRD3
10 associative learning GO:0008306 9.78 DRD1 DRD2 DRD5
11 adult behavior GO:0030534 9.77 DRD2 NRXN1 SLITRK1
12 negative regulation of blood pressure GO:0045776 9.77 DRD2 DRD3 DRD5
13 arachidonic acid secretion GO:0050482 9.75 DRD2 DRD3 DRD4
14 negative regulation of protein secretion GO:0050709 9.74 DRD2 DRD3 DRD4
15 behavioral response to cocaine GO:0048148 9.73 DRD1 DRD2 DRD3 DRD4
16 behavioral fear response GO:0001662 9.72 DRD1 DRD4
17 response to morphine GO:0043278 9.72 DRD2 DRD3
18 regulation of presynapse assembly GO:1905606 9.72 NRXN1 SLITRK1
19 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.72 DRD1 NRXN1
20 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.72 DRD1 DRD3 DRD5
21 synaptic membrane adhesion GO:0099560 9.71 NRXN1 SLITRK1
22 temperature homeostasis GO:0001659 9.71 DRD1 DRD2
23 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.71 DRD2 DRD3
24 transmission of nerve impulse GO:0019226 9.71 DRD1 DRD5
25 response to iron ion GO:0010039 9.71 DRD2 SLC6A3
26 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.71 DRD2 DRD3 DRD4
27 dopamine receptor signaling pathway GO:0007212 9.71 DRD1 DRD2 DRD3 DRD4
28 long-term synaptic depression GO:0060292 9.7 DRD1 DRD5
29 striatum development GO:0021756 9.7 DRD1 DRD2
30 grooming behavior GO:0007625 9.7 DRD1 DRD2
31 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.7 DRD1 DRD2 DRD5
32 positive regulation of renal sodium excretion GO:0035815 9.69 DRD2 DRD3
33 dopamine transport GO:0015872 9.69 DRD1 SLC18A2 SLC6A3
34 G protein-coupled receptor internalization GO:0002031 9.68 DRD2 DRD3
35 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.68 DRD3 DRD4
36 peristalsis GO:0030432 9.68 DRD1 DRD2
37 adenohypophysis development GO:0021984 9.67 DRD2 SLC6A3
38 behavioral response to ethanol GO:0048149 9.67 DRD2 DRD4
39 monoamine transport GO:0015844 9.67 SLC18A2 SLC6A3
40 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.67 DRD1 DRD2 DRD3
41 synaptic transmission, dopaminergic GO:0001963 9.67 DRD1 DRD2 DRD3 DRD5
42 negative regulation of voltage-gated calcium channel activity GO:1901386 9.66 DRD2 DRD4
43 mating behavior GO:0007617 9.66 DRD1 DRD5
44 cellular response to catecholamine stimulus GO:0071870 9.65 DRD1 DRD5
45 cerebral cortex GABAergic interneuron migration GO:0021853 9.65 DRD1 DRD2
46 negative regulation of dopamine receptor signaling pathway GO:0060160 9.63 DRD2 DRD3
47 acid secretion GO:0046717 9.63 DRD2 DRD3
48 response to histamine GO:0034776 9.63 DRD2 DRD3 DRD4
49 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.62 DRD2 DRD4
50 regulation of locomotion involved in locomotory behavior GO:0090325 9.62 DRD2 DRD3

Molecular functions related to Tic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.85 DRD1 DRD2 DRD3 DRD4 DRD5
2 drug binding GO:0008144 9.56 DRD2 DRD3 DRD4 SLC6A3
3 G-protein alpha-subunit binding GO:0001965 9.43 DRD1 DRD5
4 adrenergic receptor activity GO:0004935 9.4 DRD2 DRD3
5 monoamine transmembrane transporter activity GO:0008504 9.37 SLC18A2 SLC6A3
6 dopamine neurotransmitter receptor activity GO:0004952 9.35 DRD1 DRD2 DRD3 DRD4 DRD5
7 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.33 DRD2 DRD3 DRD4
8 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.32 DRD1 DRD5
9 dopamine binding GO:0035240 9.1 DRD1 DRD2 DRD3 DRD4 DRD5 SLC6A3

Sources for Tic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....